UNCY Share Price Performance
US$4.09
0.45 (12.42%)
Price US$4.09
Share PriceUS$4.09
UNCY Community Narratives
There are no narratives available yet.
Recent UNCY News & Updates
No updates
Unicycive Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.28
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Unicycive Therapeutics, Inc. Competitors
About UNCY
- Founded
- 2016
- Employees
- 23
- CEO
- WebsiteView website
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee’s Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. More promisingly, the market is up 20% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading